News
Prediction of Type 2 Diabetes may be more effective by Novel Circulating Biomarkers and Pathways
In 2015, 29 million people in the United States had type 2 diabetes, according to the American Diabetes Association. Type 2 diabetes is generally...
Clinical Trials
Successful Industrial GMP Manufacturing of RIBOXXIM, a Novel and Highly Potent Toll-like 3 Ligand for Immunotherapy of Cancer
RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and ACCINOV, a pharmaceutical establishment for experimental drug product announced the successful...
News
Ardena launches following Pharmavize and Crystallics merger
A new early-phase contract development and manufacturing organisation (CDMO), Ardena, has launched following the merging of Pharmavize and Crystallics. The two companies came together...
Clinical Trials
Positive Dupilumab Topline Results From Phase 3 Trial In Uncontrolled Persistent Asthma Announced By Regeneron And Sanofi
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with...
Press Releases
Zavante Therapeutics Announce Agreement To Assess ZOLYD™ for Lower Respiratory Tract Infections With NIAID
Zavante Therapeutics, Inc., a biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients, has signed a Clinical Trial Agreement...
Packaging & Labelling
Research reveals costly implementation is the biggest barrier to serialization compliance
According to new industry research more than half (54%) of industry professionals believe that the cost of implementing serialization is the greatest hurdle to...
Press Releases
Bioanalytical Laboratory Expansion at Its USA Headquarters Completed By BioAgilytix
Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, has completed the expansion of the laboratory facility...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read